Abstract
Background T cell immunity is key for the control of viral infections including SARS-CoV-2, in particular with regard to immune memory and protection against arising genetic variants.
Method We recently evaluated a peptide-based SARS-CoV-2 T cell activator termed CoVac-1 in a first-in-human clinical trial and observed a favorable safety profile and induction of poly-specific T cell responses until month 3. Here, we report on long-term safety and efficacy data of CoVac-1 in healthy adults until month 12.
Findings CoVac-1 is well tolerated without long-term immune-related side effects and induces long-lasting anti-viral T cell responses in 100% of study participants. Potent expandability of CD4+ and CD8+ T cells targeting multiple different CoVac-1 T cell epitopes was observed 6 and 12 months after one single dose of CoVac-1. T cell responses were associated with the severity and the number of local adverse events at injection site. Beyond induction of T cell immunity, 89% of study participants developed CoVac-1-specific IgG antibody titers which associated with the intensity of the T cell response, indicating that CoVac-1-specific CD4+ T cells support the induction of B cell responses. Vaccination with approved COVID-19 vaccines boosted CoVac-1-specific T cell responses. Overall, a low SARS-CoV-2 infection rate was observed in the study population (8.3% of participants until month 12).
Interpretation Together, a single application of CoVac-1 elicits long-lived and broad SARS-CoV-2-specific T cell immunity, which further supports the current evaluation of our T cell activator in patients with congenital or acquired B cell defects (NCT04954469).
Funding This trial is funded by the Ministry of Science, Research and the Arts Baden- Württemberg., Germany
Evidence before this study T cells have an important role for COVID-19 outcome and maintenance of SARS-CoV-2 immunity, even in the absence of humoral immune responses. Thus, the induction of SARS-CoV-2 T cell immunity is a central goal for vaccine development and of particular importance for patients with congenital or acquired B cell deficiencies. We developed the peptide-based T-cell activator CoVac-1, composed of SARS-CoV-2 T-cell epitopes derived from various viral proteins. In a Phase I trial in healthy adults, CoVac-1 induced profound T-cell immunity after single dose administration in 100% of participants. The multifunctional Th1CD4+ and CD8+ T-cell response induced by CoVac-1 surpassed those occurring after naturally SARS-CoV-2 infection as well as after vaccination with approved vaccines.
Added value of this study Here we present the final data of our Phase I trial, evaluation of safety and immunogenicity of CoVac-1 until 12 months after administration. CoVac-1 is well tolerated without long-term immune-related side effects and induces long-lasting and broad anti-viral T cell responses in all study participants, which associate with low-infection rate in the study population.
Implications of all the available evidence Various vaccines have been approved to prevent severe COVID-19, primarily designed to induce a spike-specific humoral immune response. CoVac-1 is the first T-cell activator for induction of broad and sustained SARS-CoV-2 T-cell immunity. Accordingly, CoVac-1 may well serve as a (complementary) vaccine to induce T cell immunity, particularly in elderly and immunocompromised individuals with impaired ability to mount sufficient immune responses after SARS-CoV-2 vaccination with currently approved vaccines.
Competing Interest Statement
JSH, HRS, H-GR, and JSW are listed as inventors on a patent (EP 20 169 047.6) related to the SARS-CoV-2 T cell epitopes included in CoVac-1. H-GR and K-HW are listed as inventor on a patent related to the adjuvant XS15 included in CoVac-1 (DE102016005550.2). The other authors declare no competing interests.
Clinical Trial
ClinicalTrials.gov identifier: NCT04546841
Funding Statement
This work was supported by the Ministry of Science, Research and the Arts Baden-Wuerttemberg, Germany (Sonderfoerdermassnahme COVID-19, TUE17), Bundesministerium fuer Bildung und Forschung (BMBF, FKZ:01KI20130; FKZ:16LW0005; FKZ:01DP21014; FKZ:16LW0004K), the Robert Bosch Stiftung, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, Grant WA4608/1-2), the Deutsche Forschungsgemeinschaft under Germanys Excellence Strategy (Grant EXC2180-390900677), the German Cancer Consortium (DKTK), the Wilhelm Sander Stiftung (Grant 2016.177.3), the Deutsche Krebshilfe (German Cancer Aid, 70114948), the Zentren fuer Personalisierte Medizin (ZPM), the State Ministry of Baden-Wuerttemberg for Economic Affairs, Labour and Housing Construction (Grant number 3-4332.62-NMI-67, 3-4332.62-NMI-68 and 7-4332.62-NMI/55) and the EU Horizon 2020 research and innovation program (Grant agreement number 101003480-CORESMA). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial was approved by the Ethics Committee, University Tuebingen (537/2020AMG1) and the Paul Ehrlich Institute and performed in accordance with the International Council for Harmonization Good Clinical Practice guidelines
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data are available in the manuscript or the Supplementary Materials.
